Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | $8.00 | Buy | BTIG Research |
| 12/6/2021 | $7.00 | Buy | HC Wainwright & Co. |
Gainers Molecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their outstanding shares is at $367.3 million. Zentalis Pharma (NASDAQ:ZNTL) stock rose 36.83% to $5.67. The market value of their outstanding shares is at $402.2 million. Femasys (NASDAQ:FEMY) stock increased by 28.27% to $1.23. The market value of their outstanding shares is at $27.2 million. SeaStar Medical Holding (NASDAQ:ICU) shares rose 18.68% to $4.89. The market value of their outstanding shares is at $15.2 million. Nanoviricides (AMEX:NNVC) shares rose 17.68% to $1.93. The company's market cap stands at $22.8 million. CASI Pharmaceuticals (NASDAQ:CASI) sha
Across the recent three months, 4 analysts have shared their insights on VYNE Therapeutics (NASDAQ:VYNE), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $5.75, a high estimate of $5.75, and a low estimate of $5.75. Holding firm without variation
DEF 14A - VYNE Therapeutics Inc. (0001566044) (Filer)
10-Q - VYNE Therapeutics Inc. (0001566044) (Filer)
8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
BRIDGEWATER, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that its Board of Directors has approved a reverse stock split of the Company's common stock at a ratio of 1-for-18. The reverse stock split was previously approved by stockholders at the Special Meeting of Stockholders on January 12, 2023. The reverse stock split will become effective after market close on Friday, February 10, 2023 and shares will begin trading on a split-adjusted basis when the market opens on Mo
Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sale of Topical Minocycline Franchise Continues to Advance Conference call and Live Webcast Today at 8:30 am Eastern Time BRIDGEWATER, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "The third quarter marks an important turning point for VYNE, as our company is now fully enga
BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details:Wednesday, November 10th @ 8:30am Eastern TimeToll Free:855-327-6837International:631-891-4304Conference ID:10017178Webcast:https://themediaframe.com/mediaframe/webcast.html?webcastid=44cKOFEX A replay of the call will be archived on the Company's website at
VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data for VYN202, with MAD data expected in Q4 2024 BRIDGEWATER, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the three and nine months ended September 30, 2024 and provided a business update. "We continue to make excelle
VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target engagement and inflammatory biomarkers Dosing has begun in the MAD portion of the trial with results expected in Q4 2024 BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive data from the single ascending dose ("SAD") portion of its ongo
BRIDGEWATER, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that management will participate in two investor conferences in September: H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 9-11, 2024, New York, NYFormat: One-on-one investor meetings Stifel 2024 Virtual Immunology and Inflammation SummitSeptember 17-18, 2024Presentation: Tuesday, September 17, 2024 at 8:30 AM ETFormat: Fireside Chat and one-on-one investor mee
4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
BTIG Research initiated coverage of VYNE Therapeutics with a rating of Buy and set a new price target of $8.00
HC Wainwright & Co. resumed coverage of VYNE Therapeutics with a rating of Buy and set a new price target of $7.00
HC Wainwright & Co. reiterated coverage of VYNE Therapeutics with a rating of Buy and set a new price target of $11.00 from $14.00 previously
BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Subhashis Banerjee, M.D., as Senior Vice President of Clinical Development, effective as of July 8, 2024. Dr. Banerjee is a trained immunologist and rheumatologist with over 25 years of drug development experience at large pharmaceutical companies, including with the development of therapies for psoriasis and arthritic conditions. "We are pleased to welcome Dr. Banerjee to the VYNE
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024. "We are pleased to welcome Dr. Borowski to our Board of Directors during this important time in the Company's growth," said David Domzalski, President and CEO of VYNE. "With her expertise in immunology and extensive experience in the biopharmaceutical industry, Dr. Borowski will provide valuable p
4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)
SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)
SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)